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ABSTRACT: The ability to specifically silence genes by RNA
interference has an enormous potential for treating genetic
diseases. However, different drawbacks such as short
interfering RNA (siRNA) degradability by serum nucleases
and biodistribution issues still need to be overcome to develop
suitable delivery vehicles that have been proven essential in
carrying siRNA to its target. Chitosan is an attractive
biomaterial to construct gene nanocarriers as it is safe,
cheap, and amenable to chemical modifications. However, the
transfection efficiency of nanovectors based on unmodified
chitosan has revealed to be relatively low and dependent on different factors such as the biopolymer molecular weight,
deacetylation degree, charge ratio, pH, or particle size. Thus, specific strategies have been adopted to improve the transfection
efficacy of chitosan-based nanovectors. In this work, hydrophobically modified chitosans with 8-, 10-, and 12-carbon side chains
grafted to the polymeric backbone by a reductive amination process were used to develop polymeric nanoparticles by the
ionotropic gelation method. After chitosan modification, the produced nanoparticles showed a suitable combination of size and
surface charge with high siRNA loading capacities, efficient protection against serum nucleases, and satisfactory in vitro release
profiles. Importantly, the introduced structural modifications were observed to modulate the overall physicochemical
characteristics of the nanoparticles including their biological performance like their cell viability, uptake, and transfection
efficiency. In this regard, the knockdown activity of the prepared nanoparticles was tested in HeLa cells overexpressing the green
fluorescent protein after 24 and 48 h of incubation, observing a silencing activity greater than that displayed by the commercial
transfection agent Lipofectamine 2000.
1. INTRODUCTION
In comparison to conventional DNA-based gene therapy, the
use of short interfering RNAs (siRNAs) for silencing genes
through RNA interference (RNAi) has recently attracted much
attention.1 This is a biological process in which siRNA
molecules interfere in the expression of specific genes by
degrading targeted messenger RNA (mRNA) after tran-
scription; this prevents their translation and, subsequently,
leads to gene silencing. Upon introduction into cells, siRNA
joins a multicomponent nuclease complex termed RNA-
induced silencing complex (RISC). Within the RISC, siRNA
is unrolled to form single-stranded siRNA, where one strand is
integrated as a template within the RISC complex for
recognizing complementary mRNA strands. After strand
targeting, ribonucleases are activated inducing mRNA strand
cleavage and subsequent suppression of gene/protein
expression associated with mRNA codification.2,3 The non-
incorporated mRNA strand is eliminated during the siRNA
assembly process and, probably, degraded thereafter.4 RNAi is
advantageous over other therapies in terms of, for example, its
specificity and noncytotoxicity.3 In addition, the effective
administration of synthetic siRNAs in vivo and the subsequent
downregulation of an endogenous target without undesirable
side effects have been already demonstrated.5 Thanks to their
selectivity and potency, RNAi is becoming a very attractive
approach for future therapeutics to provide specific gene
expression silencing and subsequent control of gene disorders.
Nevertheless, for an effective action and potential wide-
spread use of siRNA therapeutics, several major challenges
must be first overcome: (i) the achievement of an optimal
concentration of the oligonucleotide double strands inside the
cell cytoplasms to induce effective and long-standing gene
silencing; (ii) the protection of siRNA from degradation by
serum nucleases after administration leading to enhanced half-
lives;6 (iii) the impossibility of siRNA strands to diffuse
through cellular membranes by their anionic character and size,
the former involving strong repulsive electrostatic interactions
with cell membranes.7 Therefore, the efficient, safe, and
repeated administration of siRNAs is largely dependent on the
development of suitable nanocarriers for their controlled
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transport and delivery.8 An ideal carrier for siRNA transport
and delivery should, then, fulfill the following requirements: (i)
to be able to bind and condense siRNA strands inside the
nanovehicle; (ii) to protect this therapeutic cargo from serum-
degrading enzymes; (iii) to target the therapeutics specifically
to the site of action; (iv) to facilitate/enhance cellular uptake
and internalization of the bioactive material; (v) to allow the
escape from endosomes/lysosomes into the cytosol; and
finally, (vi) to promote effective silencing and subsequent
downregulation.
Previous studies have shown chitosan as a very promising
carrier biomaterial for RNA delivery to attain an effective
expression of reporter genes in vitro and in vivo, highlighting
the potential use of chitosan as the main constituent of
nanocarriers for siRNA delivery. To establish its effectiveness,
it is key to determine the influence of the formulation
parameters on the physical and biological performances of the
formed siRNA/chitosan complexes for an effective therapeutic
response and to ensure correct siRNA protection to enzymatic
degradation. For example, Liu et al. analyzed the in vitro gene
silencing of chitosan−siRNA nanoparticles (CSNPs), elucidat-
ing that this phenomenon is strongly dependent on the
molecular weight (Mw) and degree of deacetylation of the
biopolymer.9 Katas et al. showed that the transfection
efficiency of siRNA depends on the method of siRNA
association with chitosan, with ionic gelation being the best
methodology to provide the highest biological effect.10 A
remarkable in vivo study developed by Howard et al. also
demonstrated the efficacy of nasally administered siRNA-
encapsulated chitosan NPs in transgenic mice overexpressing
the green fluorescent protein (GFP), in which significant GFP
knockdown was achieved.11 Recently, additional studies have
further investigated the role played by the biopolymer
hydrophobicity, nitrogen-to-phosphate (N/P) ratio, particle
size, and targeting ligands in the improvement of the
transfection efficiency and associated gene knockdown. For
instance, the combination of pRNA dimers with poly(ethylene
glycol) (PEG)-modified chitosan NPs functionalized with
folate gave rise to a tumor-targeting siRNA delivery system
with a much higher cargo accumulation in the in vivo target
tissue.12
However, chitosan-based siRNA delivery nanocarriers have
their own limitations. One of the main drawbacks is their low
water solubility at physiological pH, which may preclude their
successful in vivo administration. It is worth reminding that at
physiological pH, the number of available positively charged
groups in the chitosan backbone is largely reduced, which can
impede the siRNA electrostatic complexation and preclude
particle stability in vivo. Moreover, the transfection efficiency
of native chitosan is still far to be optimal, and insufficient in
vivo siRNA intracellular release levels have been achieved.13
This major issue may originate from serum proteins (albumin
and fibrinogen), which can cause particle aggregation, favoring
the probability of suffering embolism and/or enhanced
cytotoxicity. Additionally, negatively charged blood compo-
nents, mainly proteins, can compete with siRNA for binding to
the cationic biopolymer and, thus, particles can disassemble
into the bloodstream resulting in premature siRNA release
followed by degradation and/or renal clearance.14 Thus, the
chemical modification of chitosan appears as an interesting way
to provide with new physicochemical characteristics to the
chitosan biomolecule to overcome these pitfalls. Chitosan
chains bear three reactive sites for chemical modification: two
hydroxyl groups and one primary amine within the glucos-
amine units, which can be chemically modified to overcome
barriers for gene delivery; however, for nucleic acid binding,
the latter should be maintained. In this manner, several
chitosan derivatives have emerged as potentially interesting
alternatives for siRNA delivery, such as trimethyl-,15
thiolated-,16 glycol-,17 PEGylated-,18,19 guanidinylated-,20 or
alkyl-chain-modified chitosans.21 All of these modifications
resulted in improved particle solubility and stability, larger
transfection efficiencies, and/or pH independence. Among
these, hydrophobic modification of the biopolymer backbone
appears particularly interesting since it has demonstrated great
potential in enhancing the performance of gene nanovectors.
For example, the transfection efficiency of siRNA into C2C12
cell lines using alkylated chitosans with different side-chain
lengths was found to increase as the alkyl chain length
increases up to ca. eight-carbon length.22 This higher
transfection endowed by alkylated chitosans could be assigned,
on the one hand, to the enhanced chitosan−siRNA complex-
ation by the hydrophobicity-induced weakening of the
electrostatic attractions between siRNA and the cationic
nanocarrier and, on the other, to the larger nanovector uptake
through the hydrophobic domains of cell membranes.22,23
This article describes the obtention of different alkyl-chain-
modified chitosan nanovectors by the ionic gelation method
and the role played by the aliphatic side-chain length and
substitution degree in the loading, protection, stability, release
profiles, transfection, and knockdown efficiencies of siRNA to
construct suitable gene carriers. In particular, aliphatic side
chains of different lengths (octyl, decyl, and dodecyl) were
grafted to different extents in the polymer backbone to achieve
several degrees of substitution. These modified chitosans were
used to obtain chitosan−siRNA nanoparticles (CSNPs) by
means of the ionic gelation process. It was observed that the
incorporation of siRNA within the NPs was driven by a
combination of electrostatic, hydrogen, and hydrophobic
forces, as evidenced by isothermal titration experiments. This
incorporation also led to additional changes in both particle
sizes and surface charges. In this respect, unmodified CSNPs
showed, in general, bulkier sizes than the corresponding
nonderivatized unloaded counterparts (CNPs), whereas the
opposite trend was found for the modified CSNPs. The
hydrophobic modifications improved the siRNA loading and
entrapment efficiency inside the particles, providing further
protection from the surrounding medium, as well as an
additional control over the cargo release kinetics by lowering
the initial siRNA burst phase while keeping a sustained delivery
for longer times. It was observed that hydrophobically
modified CSNPs were fairly stable in physiologically relevant
medium, with slight clustering upon long incubation. To test
the cytotoxicity, transfection efficiency, and knockdown
activity of the conceived NPs, a series of in vitro experiments
were also performed in cervical cancer HeLa cells and RAW
264.7 macrophages, with an additional look at potential toxic
and transfection efficiency differences depending on the cell
type and physiology.24 HeLa cells were more sensitive than
macrophages to the presence of hydrophobically modified
CSNPs in a dose-dependent manner. Impressively, CSNPs,
comprising the hydrophobized chitosan, delivered siRNA
inside the cell cytoplasm to a larger extent than their
nonmodified counterparts thanks to their higher capability of
cellular internalization. Afterward, these modified CSNPs
manifested effective gene silencing, by inhibiting the expression
ACS Omega Article
DOI: 10.1021/acsomega.8b02875
ACS Omega 2019, 4, 3904−3921
3905
of GFP overexpressed in modified HeLa cells, slightly greater
than that of Lipofectamine 2000, a well-established trans-
fection agent.
2. EXPERIMENTAL SECTION
2.1. Materials. Chitosan with an average molecular weight
of 415 000 g/mol and 90% deacetylation degree (Fluka,
middle-viscosity grade) was regularly used. Low- and high-
viscosity-grade chitosans, also from Fluka, were used for
comparison. Sodium cyanohydroborate (NaCNBH4); octyl,
decyl, and dodecyl aldehydes; and pentasodium tripolyphos-
phate (TPP) were purchased from Sigma (Sigma-Aldrich Co.)
and used as received. A BLOCK-iT control fluorescent oligo
probe was obtained from Invitrogen (Carlsbad, MA). This
fluorescein-labeled dsRNA oligomer has the same length,
electrical charge, and structure as that of standard siRNA.
UltraPure DNase/RNase-free distilled water was from Gibco
(Life Technologies). All organic solvents were of high-
performance liquid chromatography grade, and all other
chemicals were of the highest purity commercially available.
2.2. Synthesis and Characterization of Chitosan
Derivatives. Chitosan derivatives were obtained by a
reductive amination process25−27 (see Scheme 1). As
previously described, the alkylation reaction entailed grafting
of alkyl side chains of 8, 10, and 12 carbons onto the chitosan
backbone.25,28 Briefly, 2 g of chitosan was dissolved in 110 mL
of 0.2 M acetic acid. After dissolution, 75 mL of ethanol was
added and pH was adjusted to 5.1 to avoid the precipitation of
the biopolymer. Different aldehyde proportions (5, 10, or 50%
where corresponding) diluted in ethanol were added to the
chitosan solution followed by a threefold molar excess of
sodium cyanohydroborate. Next, the reaction was allowed to
proceed under stirring for 24 h at room temperature. The
alkylated chitosan was precipitated in ethanol, the pH adjusted
to 7 and, then, the precipitate washed several times in ethanol/
water mixtures of increasing ethanol content from 70 to 100%
(v/v).
Chitosan substitution degree was determined by 1H nuclear
magnetic resonance (1H NMR) spectroscopy (Figure S1)
using a Bruker (XRD-500) instrument operating at 500 MHz
and 11.74 T. The samples were prepared by dissolving 5 mg of
the different modified chitosans in 0.5 mL of a 2% (v/v) DCl/
D2O mixture at pH 3.2.
2.3. Preparation of Chitosan NPs. Chitosan nano-
particles (CNPs) and chitosan−siRNA nanoparticles
(CSNPs) were prepared by ionic gelation through the cross-
linking of TPP and chitosan chains, as previously described,29
with some modifications. Briefly, 1 mg/mL chitosan was
dissolved in 0.2 M acetic acid (pH 4.2) and stirred overnight at
room temperature. Afterward, 0.5 mg of TPP was dissolved in
0.75 mL of RNAse-free water and this mixture was directly
dropped into the chitosan solution under constant stirring. For
the production of CSNPs, a specific amount of siRNA was
dissolved in 0.75 mL of TPP solution before its dropwise
addition into chitosan one. Magnetic stirring was carried out at
700 rpm at room temperature for 30 min. The synthesized
nanoparticles (NPs) were centrifuged at 15 000 rpm for 20
min and resuspended in RNAse-free distilled water. Finally,
particle samples were filtered (Millipore Millex filters, 0.45 μm
pore size) and stored at 2−8 °C.
2.4. Dynamic Light Scattering (DLS). Dynamic light
scattering (DLS) measurements were performed using a static
light scattering/DLS instrument (ALV-5000F, ALV-GmbH,
Germany) equipped with a diode-pumped Nd:YAG solid-state
laser (Coherent Inc., CA) supplying vertically polarized
incident light (λ = 488 nm) and an ALV SP-86 digital
correlator. Measurements were made at a scattering angle of θ
= 90° to the incident beam with a duration of 2−5 min. Prior
to measurement, samples were filtered and thermally
equilibrated for 10 min. The intensity scale was calibrated
against scattering from toluene, and each measurement was
repeated at least three times. The obtained correlation
functions were analyzed by the CONTIN method.30 Values
of the apparent hydrodynamic radius (RH) were calculated







where kB is the Boltzmann constant, T the temperature, η the
solvent viscosity, and Dapp the apparent diffusion coefficient
derived from the CONTIN analysis.
2.5. ζ-Potentials. ζ-Potentials of CNPs and CSNPs were
measured using a Nano ZS-90 instrument (Nanoseries,
Malvern Instruments, U.K.), which allows the analysis of
particle electrophoretic mobilities. From this quantity, ζ-
potentials can be derived by means of the classical
Smoluchowski equation with the Smoluchowski approximation





where α, ε, ζ, and η denote the electrophoretic mobility,
permittivity of the media, ζ-potential of the particles, and
viscosity of the media, respectively. To perform the measure-
ments, each particle solution was loaded into a capillary cell
and thermally equilibrated at 25°C. The number of runs was
automatically set by the software (>20), and the measurements
were made at least in triplicate. Results were reported as the
mean ± standard deviation.
2.6. Transmission Electron Microscopy (TEM). To
obtain TEM images, a drop of 5 μL of CNP and CSNP
suspensions was applied on the top of carbon-coated copper
grids, blotted, washed, negatively stained with 2% (w/v)
phosphotungstic acid, air-dried, and examined with a JEOL
JEM 1011 (Japan) transmission electron microscope at 120
kV. Samples were diluted, when required, before deposition on
the grids.
2.7. Quantitative Analysis of siRNA in CSNPs. To
determine the encapsulation efficiency (EE) and loading
capacity (LC) of the obtained nanocarriers, CSNPs were
centrifuged at 15 000 rpm at 20 °C for 20 min. Next, the
siRNA concentration in the supernatant was determined by
UV−vis and fluorescence spectroscopies using the supernatant
Scheme 1. Scheme of the Alkylation Reaction Process for
Derivatization of the Chitosan Backbone
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of each CNP as a blank. UV−vis plots were made at 260 nm
subtracting the potential contribution at 280 nm from small
protein residues in the solution media. Fluorescence spectra
were recorded by setting λex = 494 nm and λem = 519 nm. UV−
vis spectra were recorded using a Cary Bio 100 UV−vis
spectrophotometer (Agilent Technologies), whereas fluores-
cence spectra were recorded using a Cary Eclipse spectropho-
tometer (Agilent Technologies). Each sample was measured in
triplicate from three different particle batches, and the final
















2.8. Binding Efficiency Assay. Agarose gel electro-
phoresis was used to determine the successful binding of
siRNA to chitosan. The different modified chitosan-based
nanovectors encapsulating an initial feed of 150 pmol of siRNA
were loaded in each well (20 μL). Gel electrophoresis
experiments were performed at a constant voltage of 150 V
during 30 min using 2% agarose gels. siRNA was stained with
SYBR Green I (Life Technologies, Thermo Fisher Scientific)
in a 1:10 000 dilution in TE Buffer (10 mM Tris·HCl, pH, 1
mM sodium ethylenediaminetetraacetate (EDTA)) for 15 min.
An E-Gel Safe Imager Real-Time Transilluminator and an E-
Gel iBase Power System (Invitrogen, Thermo Fisher
Scientific) were used to visualize the samples. Photographs
were taken with a CANON IXUS 155 camera.
2.9. siRNA Serum Stability Assay. Following a previously
reported protocol,10 CSNPs loaded with 150 pmol of siRNA
were incubated at 37 °C in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 5 and 50% (v/v) of
fetal bovine serum (FBS). At different times (0, 0.5, 2, 4, 7, 24,
48, and 72 h), 100 μL of each particle’s solution was removed
and stored at −20 °C until gel electrophoresis was performed.
To carry out the experiments, the serum activity was first
stopped. To do that, samples were incubated at 80 °C for 10
min and, then, 5 μL of heparin (1000 U/mL) was added for
displacing the siRNA from CSNPs. The analysis of siRNA
integrity was carried out using a 4% agarose gel, as described
above.
2.10. Isothermal Titration Calorimetry (ITC). The
interactions and binding between siRNA and the different
modified chitosans were analyzed using a VP-ITC titration
microcalorimeter (MicroCal Inc., Northampton, MA) at 25
°C. The sample and reference cells of the calorimeter were
filled with chitosan (1.06 μM, 10 mM acetate buffer, pH 4.8)
and pure buffer solutions, respectively. Next, the anionic
solution containing siRNA (2 μM) and TPP (2.88 mM)
dissolved in RNAse-free water was introduced into the
thermostated sample cell using a computer-controlled syringe
and stirred at 350 rpm. Each experiment consisted of an initial
2 μL injection (neglected in the analysis) followed by other 27
10 μL injections with a spacing time of 600 s, which is enough
time for the heat signal to return to the baseline. The ITC plots
represent the heats of injection normalized by the siRNA
concentration added per injection, Q*, as a function of the
siRNA/chitosan molar ratio. The heats of dilution correspond-
ing to the titration of the anionic solution into pure acetate
buffer were subtracted to obtain the net binding heats. All
experiments were carried out in triplicate.
The raw ITC data were analyzed as described previ-
ously.31,32 Briefly, the binding isotherms were fitted to a two-
binding-site model, which makes use of the Langmuir isotherm
binding equilibrium for two independent types of associations
θ θ= · · · ·Δ + · ·ΔQ M V n H n H( )1 1 1 2 2 2 (4a)
where Q is the heat per injection; M the macromolecule
concentration (in this case, siRNA); V the cell volume; n and
ΔH are the stoichiometry and enthalpy of interactions,
respectively; θ the fraction of ligand bound to the macro-
molecule; and the subindices 1 and 2 stand for the two sets of
sites.
Using a nonlinear fitting algorithm, the former equation can
be solved for θ1 and θ2 using the equilibrium equations for
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where X is the total ligand concentration and [X] the
concentration of the free ligand (chitosan).
2.11. Colloidal Stability. The colloidal stabilities of CNPs
and CSNPs were assessed by diluting the particles (1/50) at 37
°C under different solution conditions (aqueous solutions of
different pH values ranging from 3 to 9; Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS; and
RNAse-free water),10 and moderate stirring for 5 days. ζ-
Potential and hydrodynamic sizes were acquired using a
Zetasizer Nano ZS-90 (Malvern Instruments, U.K.). Experi-
ments were performed in triplicate.
2.12. In Vitro Release Studies. siRNA release from
CSNPs was measured in vitro at a constant temperature of 37
°C under magnetic stirring (300 rpm) for several days at three
different pH values (7.4, 5.0 simulating the acidic micro-
environment of the cytoplasm,33 and pH 2.0, lying in the range
of gastric pH).34 The released siRNA concentration was
determined at different time intervals for every solution pH by
placing 1 mL of CSNPs into dialysis tubes (Spectra/Por,
MWCO 3500, SpectraLabs) immersed in 50 mL of buffer
supplemented with 10% fetal bovine serum (FBS) at the pH of
interest. At each sampling time, 1 mL of the medium was
withdrawn and replaced with the same volume of fresh buffer
to maintain the required sink conditions. The siRNA content
in the supernatant was measured by means of UV−vis and
fluorescence spectroscopies using calibration curves in the
corresponding buffers, as previously described. Assays were
carried out in triplicate.
2.13. Cell Culture. HeLa cervical cancer cells and HeLa-
GFP-modified cells (Cell Biolabs, San Diego, CA) were grown
at standard culture conditions (5% CO2 at 37 °C) in DMEM
supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 1% (v/
v) penicillin/streptomycin, 1 mM sodium pyruvate, and 0.1
mM MEM nonessential amino acids (NEAAs). RAW 264.7
macrophages were cultured in 50:50 DMEM/F12-Ham mixed
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medium supplemented with 10% (v/v) FBS, 2 mM L-
glutamine, 1% (v/v) penicillin/streptomycin, 1 mM sodium
pyruvate, and 0.1 mM NEAA (37 °C, 5% CO2, in humidified
atmosphere).
2.14. In Vitro Cell Cytotoxicity. The cytotoxicity of
CSNPs was assayed in vitro using the cell counting kit-8
(CCK-8) cytotoxicity assay. Cervical HeLa cancer cells and
RAW 264.7 macrophages at a confluence of 80−90% were
seeded into 96-well plates (100 μL, 1.5 × 104 cells/well) and
grown for 24 h at standard culture conditions. After 24 h, 100
μL of known CNPs and CSNPs concentrations diluted in the
corresponding cell culture media was injected into the wells
and incubated for 24 and 48 h, respectively. Some cells were
transfected with 1 mM siRNA BLOCK-iT control fluorescent
oligo (Invitrogen) using Lipofectamine 2000 as a positive
control (Life Technologies, Carlsbad, CA) following the
manufacturer’s instructions. Some wells were also left without
NPs as a negative control (blank). After the corresponding
incubation time, the culture medium was discarded, cells
washed with 10 mM phosphate-buffered saline (PBS) (pH
7.4) several times, and new fresh medium (100 μL) added.
Next, 10 μL of CCK-8 reagent was injected into each well.
After 2 h, the absorption at 450 nm was measured with an
UV−vis microplate absorbance reader (Bio-Rad model 689).







where Abssample is the absorbance at 450 nm for full samples
and Absblank is the absorbance in the absence of NPs.
2.15. Cellular Uptake and Gene Silencing by
Fluorescence Microscopy. CSNP cell internalization was
monitored by confocal microscopy by seeding HeLa, HeLa-
GFP, and RAW 264.7 cells on poly-L-lysine-coated glass
coverslips (12 × 12 mm2) placed inside six-well plates (3 mL, 5
× 104 cells per well grown for 24 h at standard culture
conditions). Then, 250 μL corresponding to 0.5 mg of NPs
containing ca. 37 pmol of siRNA was added. After incubation,
the NP-containing cells were washed three times with PBS
(pH 7.4) and, then, fixed with paraformaldehyde 4% (w/v) for
10 min, washed with PBS, permeabilized with 0.2% (w/v)
Triton X-100, and stained with 4,4-difluoro-4-bora-3a,4a-diaza-
s-indacene (BODIPY) Phalloidin (Invitrogen). Afterward, cells
were washed again with PBS, mounted on glass slides stained
with ProLong Gold antifade 4′,6-diamidino-2-phenylindole
(DAPI) (Invitrogen), and kept for 24 h at −20 °C. Samples
were visualized with a 63× objective using an epifluorescence
microscope Leica DMI6000B equipped with a Leica AF6000
modular system and a DFC3665FX camera (Leica Micro-
systems GmbH, Heidelberg, Mannheim, Germany). In the
obtained images, the blue channel corresponded to DAPI (λex
= 355 nm), the red one to BODIPY Phalloidin (λex = 633 nm),
and the transmitted light was obtained in differential
interference contrast mode. Finally, the green channel
corresponded to the excitation of the fluorescein isothiocya-
nate (FITC)-doped siRNA fluorescent oligo (Invitrogen). The
same channel was used for the excitation at 355 nm of the
green fluorescent protein in HeLa-GFP cells.
2.16. Cellular Uptake and Gene Silencing by Flow
Cytometry. The cellular siRNA uptake in HeLa cells was
additionally quantified by measuring the fluorescence of a
FITC-labeled ds-siRNA oligo (Invitrogen) encapsulated into
CSNPs by flow cytometry. HeLa cells expressing GFP were
used to investigate the gene-silencing efficiency of CSNPs
loaded with a specific siRNA inhibiting the fluorescence of
overexpressed GFP (from Ambion). Normal HeLa cells were
used as a negative control, and nontransfected HeLa-GFP cells
were used as a positive one. siRNA transfected with
Lipofectamine 2000 was used as an additional transfection
reference. Cells (2 × 105 per well) were washed once with PBS
and, then, harvested with 0.05% trypsin/0.025% EDTA
followed by several washes at 1200 rpm for 4 min and
resuspension in 1 mL of PBS. The gene-silencing efficiency was
determined by collecting fluorescence data through flow
cytometry (BD FACSAria IIu, BD, Franklin Lakes, NJ). In
all analyses, 2 × 105 events were acquired, scored using a
FACSAria II analyzer (BD, Franklin Lakes, NJ), and processed
by the PC FACSDiva software program (BD, Franklin Lakes,
NJ). Cell count was always performed per 106 events.
Transfection efficiency was expressed as the percentage of
the fluorescence intensity of gathered cells compared to the
total fluorescence intensity of nontransfected HeLa-GFP cells
(positive control).
3. RESULTS AND DISCUSSION
3.1. Preparation and Characterization of Chitosan
NPs. Chitosan NPs were prepared by means of the ionotropic
gelation method. This procedure does not use organic solvents
or sonication (although optional) common to other prepara-
tive methods, which may be harmful for peptides and proteins
by altering their structural conformations (see Supporting
Information for details). For NP formation, the pKa of amino
groups of the derivatized chitosans used herein ranged from
6.5 to 6.8. Therefore, more than 90% of amines were
protonated and positively charged at pH 5.5. The pKa values
of phosphate groups of siRNA were close to zero,35 so more
than 99% were negatively charged at pH above 2.0. The
physicochemical characterization of chitosan (CNPs) and
chitosan−siRNA (CSNPs) NPs was investigated using an
unmodified medium-molecular-weight chitosan (CM), and the
same biopolymer was derivatized with octyl aldehyde or
dodecyl aldehyde chains with a 5, 10, and 50% degree of
substitution on the polymer backbone, unless otherwise stated.
This choice was based on the sizes and ζ-potentials of the
obtained NPs (see Figure S2), which should ensure a good
colloidal stability, long circulation times, and enhanced passive
accumulation at the target site. Moreover, CNPs and CSNPs,
based on a chitosan derivatized with decyl aldehyde at a
substitution degree of 10%, were also prepared to compare the
effect of the hydrophobic chain length with a determined
grafting density on the physicochemical properties of the
complex particles formed. The nomenclature used to label the
different chitosan-based NPs is summarized in Table S1.
To determine the influence of the substitution of hydro-
phobic chains on the size and surface electrical charge of
CNPs, DLS and ζ-potential data were obtained at 37 °C.
Furthermore, TEM images were acquired to get insight into
the NP morphology. Some differences in ζ-potentials and
particle sizes arose when the chitosan backbone was modified
to different extents with aliphatic chains of several lengths, as
observed in Figure 1. For CNPs containing derivatized
chitosan with a 5% substitution degree, ζ-potentials slightly
increased as the aliphatic chain length increased. Conversely,
the opposite trend was observed at higher substitution degrees.
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This can be explained based on the assumption that at lower
substitution degrees, the uncharged, hydrophobized side chains
of chitosan might have preferably arranged themselves toward
the interior of CNPs, allowing a relatively larger exposure of
their positively charged amine groups to the particles’ surface.
In other words, when the substitution degree increased, lower
surface charges of CNPs were noted as a consequence of (i)
the reduction in the number of protonated amines upon
substitution,26,27 and/or (ii) the potential presence of side
chains at the NP surfaces due to packing constraints, which
additionally screened the cationic surface charges.
The average sizes of nonhydrophobized CNPs (rh = 66 ± 5
nm) were smaller than those of the hydrophobized ones (see
Figure 1b), which ranged from ca. 70 to 140 nm depending on
the side-chain length and substitution degree.36 The hydro-
phobic segments of derivatized chitosan of CNPs might have
pointed inward, giving rise to denser cores and increase in size.
This effect was more evident for CNPs made of derivatized
chitosan with the lowest degree of substitution (5%), provided
that all aliphatic chains were anchored in the NP cores, in
agreement with ζ-potential values. In contrast, particle sizes
generally decreased as the degree of substitution increased,
seemingly as a consequence of a stronger compaction of CNPs
cores to avoid the exposure of their hydrophobic side chains to
water, especially noticeable for those bearing 12-carbon ones.
Since the complete packing of substituting side chains inside
the particle cores is not probable, a rearrangement of some of
these on/near the NP surfaces might have also taken place,
which is in agreement with ζ-potential data. On the other
hand, it was observed that the aliphatic chain length played a
key role in determining NP size, particularly for those particles
containing derivatized chitosan with high degrees of
substitution, which had smaller sizes.25,28 Moreover, particle
hydrodynamic radii were observed to decrease by ca. 30 nm
when the solution temperature increased from 25 to 37 °C. It
is worth mentioning that previous works have shown larger
chitosan-based NPs produced by means of ionotropic gelation
than those obtained in this work.22,36,37
TEM images of CNPs (Figure 2) were obtained for the
different types of derivatized chitosans. The CNP morphology
was almost spherical, especially for unmodified CNPs, with
some surface roughness. This effect was more clearly seen for
CNPs bearing substituted short-length side chains, which
displayed a certain hairy appearance (Figure 2d−f) in contrast
to those bearing 12-carbon ones, displaying smoother surfaces.
CNPs’ average sizes were in agreement with those obtained by
DLS.
3.2. Energetics of CSNP Formation. The capability of
any given delivery system to avoid premature dissociation and
promote cargo release to the target organ or tissue is strongly
related to the binding affinity between the therapeutic
macromolecule and the selected vector. Moreover, the addition
of siRNA together with TPP molecules during the ionic
gelation process has previously led to better gene-silencing
activities compared to other methods for particle/polyplex
formation.10 An effective way to assess the involved
interactions is to measure the heats produced/absorbed in
such a complexation process and evaluate the associated
binding thermodynamic quantities. To this purpose, ITC has
become one of the most useful techniques to analyze the type
and extent of interactions playing a role upon complexation of
siRNA and subsequent NP formation. To determine the
siRNA/chitosan heats of binding in the presence of the TPP
cross-linker during the NP formation process, two sets of
experiments were carried out; that is, anionic solutions
containing siRNA with TPP and only TPP (as a control)
were titrated into the sample cell containing a chitosan
solution. Then, the net heats of interaction between siRNA
and chitosan along the NP formation process were obtained
after subtraction of the heats evolved from the control
experiment. In this way, heats from siRNA dilution and
TPP−chitosan interactions were somehow neglected. The
influence of the nature and degree of substitution in the
chitosan backbone on the energetics of NP formation and
siRNA entrapment was also assessed by selecting the following
chitosan types as components of the NPs: CM, C8Mb, C8Mc,
and C12Mc.
Figure 3 shows the net heats of interaction upon injection of
a siRNA + TPP solution into chitosan solutions (after
subtraction of the heat evolved after the titration of TPP
into the same chitosan solution) as a function of the siRNA/
chitosan molar ratio for different types of hydrophobically
modified chitosans. The solid lines represent the fittings to the
experimental data. Table 1 shows the derived thermodynamic
parameters. From Figure 3, siRNA/chitosan interactions are
characterized by initial electrostatic interactions and hydrogen
bonding between the biopolymer and siRNA as shown by the
negative values of the heats of interactions (ΔHi, where the
subscript denotes the binding site; see below). ΔHi
progressively increased, becoming less negative, as the
siRNA/chitosan molar ratio increased. This finding is
consistent with those reported for other systems such as
protein−drug28,31,38 and polyelectrolyte−polyelectrolyte sys-
tems, such as chitosan−DNA interactions.32 As the siRNA/
chitosan molar ratio further increased, the evolved heats
Figure 1. (a) ζ-Potentials of derivatized CNPs at 37°C for 0, 8 10,
and 12 carbons in the aldehyde side chains with 5, 10, and 50% of
substitution degrees. (b) Hydrodynamic radii of unmodified, 8-
carbon, 10-carbon, and 12-carbon derivatized CNPs at 25 and 37 °C.
ACS Omega Article
DOI: 10.1021/acsomega.8b02875
ACS Omega 2019, 4, 3904−3921
3909
became positive (ca. 0.02−0.04), depending on the type of
chitosan, and then passed through an endothermic maximum
to subsequently decrease again. In this regard, the increasing
positive ΔQi values may be ascribed to the dehydration of
chitosan and siRNA chains, the charge-shielding effects upon
mutual interaction, and the important role of hydrophobic
interactions. Furthermore, the subsequent endothermic
decrease might be generated by dipole−dipole interactions of
water molecules favorably oriented toward adjacent formed
NPs, as observed for other systems.39 Finally, a plateau region
was observed at the largest siRNA/chitosan molar ratios
(>0.14) corresponding to dilution effects.
Regarding the thermodynamic characterization, Table 1
summarizes the enthalpy, entropy, binding constant, and
stoichiometry of siRNA/chitosan binding derived on the basis
of the two-binding-sites model. As observed, binding of siRNA
to the differently modified chitosans involved binding
constants on the order of ca. 107−108 and 106−107 for the
first and second classes of binding sites, respectively. It was
noticed that the shorter the side chain of the biopolymeric
backbone, the larger the binding constant was. This could be
attributed to the higher availability of free amine groups to
electrostatically interact with the phosphate ones of siRNA in
chitosan derivatives bearing shorter side chains and lower
extents of substitution. It is worth mentioning that much lower
levels of second-class binding constants might be expected, as a
consequence of superimposed steric restrictions. However, the
large enhancement of hydrophobic interactions partially
compensates this point.
The stoichiometry of binding is fractional (n values less than
1.0) corresponding to the interaction of multivalent substrate/
ligands.40 Concerning the enthalpy of interaction, the relatively
high exothermic enthalpies for the first class of binding sites
denote the predominance of hydrogen and electrostatic
interactions, whereas the large positive enthalpies for the
Figure 2. TEM images of CNPs obtained from (a) CL, (b) CM, (c) CH, (d) C8Ma, (e) C8Mb, (f) C8Mc, (g) C12Ma, (h) C12Mb, and (i)
C12Mc chitosans. Sample nomenclature corresponds to that stated in Table 1.
Figure 3. ITC experiments showing the evolution of the heats of
interaction as a function of the [siRNA]/[chitosan] molar ratio for
(■) CM, (●) C8Mb, (▲) C8Mc, and (⧫) C12Mc at 25 °C in
aqueous solution. Red lines represent the fitting of experimental data
to the two-biding-site model used.
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second class point to the large predominance of hydrophobic
forces in the binding process. This was additionally verified by
the change in the entropy of binding, which pointed to a clear
enthalpy-driven process for the early stages of the binding
process (shown by negative values in ΔSi) and an entropically
driven one for the second set of binding sites as shown by the
positive values observed. This behavior might be related to the
release of water molecules to the solvent and molecular
rearrangements of the polymeric chains within the modified
CNPs at this stage.
3.3. siRNA Entrapment inside Chitosan NPs. To
elucidate the optimal siRNA loading extent inside the
biopolymeric particles for effective silencing, we analyzed the
entrapment efficiencies (EEs) and loading capacities (LCs) in
the derivatized chitosan-based NPs at different initial siRNA
concentrations. Four initial amounts (50, 100, 150, and 250
pmol) of the genetic material with the different hydrophobized
chitosans were mixed with the TPP solution to obtain CSNPs
following the methodology described in the Section 2. From
Table S2 (see SI), it can be observed that the lower the siRNA
amount fed, the lower the LC obtained as a result of the
uncompleted saturation of NPs within the concentration range
analyzed. In addition, lower EE and LC values were obtained
for nonderivatized CSNPs compared to those for the
hydrophobized ones; those formed by medium-molecular-
weight chitosan were the most effective, especially at the lowest
Table 1. Thermodynamic Parameters of Interaction between siRNA and Chitosan upon the Formation of CSNPsa
CSNP 108 Ki (M
−1) 10−2 ni 10
3 ΔHi (kcal/mol) ΔSi (kcal/(mol K))
CM 2.8 ± 0.5 2.6 ± 0.3 −7.4 ± 0.4 −24.8 ± 3.2
0.3 ± 0.01 3.4 ± 0.7 2.2 ± 0.3 7.5 ± 0.6
C8Mb 1.4 ± 0.2 7.7 ± 0.5 −6.8 ± 0.5 −22.5 ± 2.1
0.5 ± 0.1 0.06 ± 0.01 4.2 ± 0.2 14.2 ± 0.3
C8Mc 1.3 ± 0.1 0.2 ± 0.3 −4.3 ± 0.2 −14.2 ± 1.6
0.2 ± 0.1 5.1 ± 0.8 3.1 ± 0.1 10.5 ± 1.7
C12Mc 0.6 ± 0.1 0.6 ± 0.2 −4.9 ± 0.3 −16.3 ± 2.3
0.07 ± 0.01 1.9 ± 0.06 2.8 ± 0.4 9.4 ± 1.4
aK, binding equilibrium constant; n, binding stoichiometry; ΔH, enthalpy changes; ΔS, entropy changes.
Figure 4. (a) Hydrodynamic radii and (b) ζ-potentials of CNPs and CSNPs in aqueous solution. TEM images of CSNPs loaded with 150 pmol of
siRNA for (c) 12Mc and (d) 8Mb.
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siRNA amounts fed. Although a decrease in LC and EE might
be expected when the number of free amino groups is reduced
upon aliphatic side-chain substitution, these quantities
strikingly increased upon chitosan derivatization. For example,
it is remarkable that EEs for hydrophobized CSNPs were
twofold higher than those of nonmodified ones. Hence,
hydrophobic modifications could improve the gene loading/
entrapment capacity and might provide further control over
the cargo release kinetics by modification of the existing
intermolecular interactions (see below).22,23,25,28,41,42 More-
over, EE values were barely constant for the derivatized CNPs
independently of the fed siRNA amount, in contrast to
nonderivatized ones for which a maximum EE was found at
150 pmol.
It is also worth mentioning that similar derivatized chitosans
were previously used to entrap the protein insulin in CNPs.25
In that study, maximum values of EE and LC were attained for
NPs consisting of derivatized chitosan with a degree of
Scheme 2. Scheme Depicting Possible siRNA and Side-Chain Distribution within CSNPs
Figure 5. (a) Temporal evolution of ζ-potentials of CSNPs for 3 days in RNAse-free water at 37 °C. (b−d) Temporal size evolution of CSNPs for
5 days at 37 °C in RNAse-free water (open symbols) and DMEM supplemented with 10% FBS (solid symbols). (b) NPs containing unmodified
chitosans with (■, □) high, (●, ○) medium, and (▲, △) low Mw.. (c) NPs containing 8-carbon and (d) 12-carbon derivatized chitosans with (■,
□) 5%, (●, ○) 10%, and (▲, △) 50% degree of substitution.
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substitution of 10%, whereas those of 50% showed the lowest
values. Possibly, the competitiveness between protein complex-
ation and compaction of the hydrophobic side chains in the
NP core might explain that outcome. Nevertheless, neither the
length of the aliphatic side chains nor the substitution degree
of the chitosans forming the NPs showed statistically
significant differences in both the values of LC and EE for
siRNA encapsulation.
On the other hand, a gel electrophoresis assay additionally
confirmed the siRNA complexation into CSNPs. The
concentration of CSNPs was selected to get a final siRNA
concentration of 90 nM per well. As observed in Figure S3, free
siRNA (lane 1) exhibited a trailing band usually associated
with siRNA degradation, and no fluorescence was observed in
the associated well. Nevertheless, for the remaining lanes, a
strong fluorescence was observed indicating that siRNA was
inside the CSNPs, and traces of nonencapsulated siRNA were
washed away after the cleaning steps (see Section 2 for details).
In addition, NP sizes and ζ-potentials of the different types
of CSNPs initially loaded with 150 pmol of siRNA were
determined by DLS and electrophoretic mobility analysis,
respectively (see Figure 4). CSNPs with a feed of 150 pmol
were chosen for further studies because they showed a suitable
balance between the initial fed concentration and high EE and
LC values. As depicted in Figure 4a, nonderivatized CSNPs
showed, in general, bulkier sizes than their empty counterparts
(CNPs),43 with this trend being strikingly different when the
NPs were formulated with derivatized chitosan. As previously
discussed, this might be a consequence of the compaction of
NP cores to avoid the exposure of their aliphatic side chains to
the aqueous medium, thus promoting collective interactions
inside the particles, particularly with entrapped siRNA
molecules. Conversely and as noted for CSNPs with chitosans
modified with a 12-carbon side chain, the excluded volume
effect of polymer chains might have precluded an effective NP
packing leading to an NP size enlargement. Based on the
aforementioned results, one might see some competition
between cargo complexation and the compaction of the
chitosan hydrophobic side chains in the NP cores, which
definitively controlled the overall characteristics of the
NPs.44,45
TEM images would also support our previous view. Figure
4c,d shows that derivatized 8Mb-CSNPs displayed a smooth
outer shell suggesting that side chains were located inside (see
Scheme 2). Conversely, 12Mc-CSNPs showed a hairy shell
indicating that some segments of the side chains were located
at the NPs’ surfaces.
This picture was also corroborated by ζ-potential data. ζ-
Potentials for all CNPs and CSNPs tested were relatively high
and positive (Figure 4b), which is expected to result in a good
colloidal stability (see below for details). As mentioned
previously, such values roughly decreased with both the
molecular weight and substitution degree of the chitosan
backbone. As opposed to bare NPs, modified NPs possess
roughly constant ζ-potential values regardless of the graft
density and side-chain length. These observations would,
hence, support DLS data and our hypothesis that hydrophobic
side chains might have localized themselves inward, avoiding
contact with water through entanglements with the rigid
siRNA and, at the same time, displacing the charged amine
groups of chitosan to the NP outer shell (see Scheme 1). As
depicted by ITC data (see above) and inferred by
others,28,46,47 hydrophobic interactions inside NPs seem to
play an important role in the complexation process, which
further supports our previous hypothesis.25
3.4. Colloidal Stability of CSNPs. Suitable size
distributions and colloidal stability of CSNPs are crucial
factors for their successful biopharmaceutical application. For
example, the evolution of the particle size affects not only
endocytosis by tumoral cells but also the NPs’ ability to evade
recognition and clearance by the reticuloendothelial system.
Hence, we next analyzed the temporal evolution of particle size
and ζ-potentials under different conditions as suitable
indicators of the colloidal stability of the as-obtained CSNPs.
Upon incubation for 3 days in water at 37 °C, ζ-potentials of
derivatized CSNPs remained almost unchanged (Figure 5a). In
addition, the size temporal evolution of unmodified and
derivatized CSNPs analyzed by DLS for 5 days in aqueous
solution at 37 °C (Figure 5b−d) denoted that 8- and 12-
carbon derivatized CSNPs were very stable in water, as shown
by the barely constant particle sizes, during the whole
incubation period. It can be observed that 12-carbon
derivatized CSNPs displayed again larger sizes in water
compared to 8-carbon hydrophobized ones since the side
chains would be not completely packed into the particle core
as they are exposed to the solvent as previously mentioned.
Therefore, this may be considered an additional clue of the
exposure of longer side chains near/on the particles surfaces as
a result of their inefficient packing inside the particle cores. For
the NPs, containing unmodified chitosans, a certain size
decrease was observed, during the first 24 h, which could be
related to some siRNA release from the particles and/or partial
hydrolysis induced by the scission of polymeric chains.48
Conversely, in DMEM supplemented with 10% (v/v), FBS
particle sizes were observed to continuously rise for the first 48
h of incubation and then remained barely constant. Such
increases may arise from the formation of aggregates among
the CSNPs (from 3 to 6 units, in terms of a single NP size)
owing to protein adsorption onto the NP surfaces, particularly
serum albumin, through electrostatic and hydrophobic
interactions, giving rise to a protein biocorona in a process
known as opsonization.49 Together with this, some NP
agglomeration, provoked by solution ionic strength, may
occur.50 Interestingly, it could be observed that CSNPs
based on the 12-carbon derivative of chitosan displayed
smaller size increments compared to those of 8-carbon
derivatives. This could be explained based on the existence
of larger electrostatic attractions between the deprotonated
carboxylic acids of proteins in FBS and the protonated amines
of chitosan at the surface of these NPs. Besides, we also think
that the 12-carbon side chains of chitosan, supposedly being
exposed near/on the particle surfaces, might somehow hinder
protein adsorption to a certain extent, thus avoiding further
size increments.51,52 However, additional studies would be
further required to confirm this point. After 48 h of incubation,
8-carbon hydrophobized CSNPs did not lead to substantial
changes in particle sizes, whereas for 12-carbon derivatized
ones, a certain decrease was observed. Finally, the stability of
the different CSNPs at different solution pH values for 5 days
was also monitored by DLS. The different types of CSNPs
showed almost no changes in particle sizes upon incubation,
except at the most extreme pH values of 3.0 and 8.0 (see
Figure S4 and further information in SI).
3.5. Stability of Encapsulated siRNA. For effective gene
expression and/or inhibition, nucleic acids or oligonucleotides
entrapped in a delivery vehicle should be protected from
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degradation by enzymes such as serum nucleases.53,54 In the
present case, if the CSNPs were unstable, siRNA would be
released.37 Then, we analyzed the influence of substitution
degree and side-chain length on the NP-entrapped siRNA
stability by selecting two extreme cases: a modified chitosan
with a short aliphatic chain and a low substitution degree
(C8Mb) and another modified chitosan with a longer side
chain and a much higher substitution degree (C12Mc). To do
that, an electrophoresis gel assay after particle incubation was
performed in DMEM supplemented with 5 and 50% (v/v)
FBS at 37 °C to ensure the ability of these modified CSNPs to
Figure 6. Mobility of siRNA following incubation in FBS-enriched medium: (a) naked siRNA; CSNPs composed of (b) CM, (c) 8Mb, and (d)
12Mc. From lane 1 to 6, incubation was done in 5% (v/v) FBS; incubation in lanes 7−12 was done in 50% (v/v) FBS. Incubation times were as
follows: 0 min (lanes 1 and 7), 30 min (lanes 2 and 8), 2 h (lanes 3 and 9), 7 h (lanes 4 and 10), 24 h (lanes 5 and 11), and 48 h (lanes 6 and 12).
Figure 7. SiRNA release from CSNPs at pH values of 7.4 (▲), 5.5 (●), and 2.0 (■). (a) NPs containing unmodified chitosans with (red) high,
(blue) medium, (green) low molecular weight. (b) 8-Carbon (c) and 12-carbon side-chain-modified CSNPs with (red) 5%, (blue) 10%, and
(green) 50% of substitution degree.
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protect siRNA from digestion by serum nucleases (see Section
2 for details).
As observed in Figure 6a, naked siRNA was intact only at the
beginning of incubation in 5% (v/v) FBS (no trailing band was
observed in lane 1 at 0 min) and fully degraded at 24 h.
Conversely, at higher serum concentration, 50% (v/v) FBS, the
presence of a trailing band in all lanes was indicative of instant
degradation, in agreement with previous reports.10
When unmodified CSNPs were incubated in 5% (v/v) FBS,
siRNA started to degrade after 30 min of incubation (no
trailing band was observed in lane 1), whereas full degradation
was observed only after 24 h (Figure 6b). Conversely, siRNA
recovered from C8Mb- and C12Mc-derivatized CSNPs was
intact after 7 h of incubation and largely complexed to the
former type of NPs and fully degraded for the latter after 48 h
of incubation (Figure 6c,d). siRNA loaded in CSNPs with the
C12Mc derivative of chitosan manifested a similar behavior as
that of naked siRNA in 50% (v/v) FBS, that is, the presence of
a trailing band in all lanes (Figure 6d, lanes 7−12). This
observation might support our hypothesis that for C12Mc-
derivatized CSNPs, siRNA would be entrapped especially
around the particle surfaces as it is largely exposed to
nucleases. Surprisingly, C8Mb-derivatized CSNPs seemed to
preclude the contact of siRNA with serum (see Figure 6c); that
is, a great part of siRNA would be still complexed with the
modified chitosan chains inside the NPs, and only a small
detachment was observed in the presence of heparin, as
confirmed by the lowest signals in the electrophoretic lanes.
Therefore, it is concluded that the present C8Mb-CSNPs
significantly protected siRNA from nuclease activity, which
may hold promise as suitable gene-delivery nanovectors.
3.6. siRNA Release. As previously mentioned, a good NP
stability is crucial for extracellular siRNA protection; however,
a suitable particle disassembly process is also needed to allow
cargo delivery and subsequent RNA-mediated gene silencing
through interactions with intracellular components such as the
RNA-induced silencing complex (RISC). Then, an appropriate
balance needs to be achieved between siRNA protection and
release for therapeutic efficacy. To this end, the ability of
CSNPs to release the entrapped siRNA was further measured
at 37 °C for several days at three different pH values
mimicking different biological media. Herein, CSNPs were
incubated at pH 7.4, 5.5, and 2.0, which mimick the
physiological pH for parenteral administration, the acidic
environment of tumors and some intracellular compartments
like lysosomes, and the gastric environment, respectively.34
As observed in Figure 7, siRNA release from CSNPs was
characterized by an initial fast release (burst phase) within the
first 9−13 h of incubation, in which the amount of cargo
released may correspond to siRNA located on/near the NP
surfaces. The burst phase was followed by a quasilinear region
leading to a sustained siRNA release for several days, as
previously observed, for example, for hydrophobic glycol
chitosan-based NPs.55 For the treatment of many different
diseases, a sustained release pattern is desired to maintain a
constant cargo concentration in blood and to prevent its
premature leakage, which can lead to undesired toxic side
effects. An additional look at the obtained release profiles
shows that the derivatization of chitosans and subsequent NP
formation allowed us to perfectly tune release rates and
extents; that is, for a given condition, there is a CSNP with a
suitable release profile. In this manner, the in vitro release
behavior of siRNA was observed to be dependent on both the
hydrophobicity of the chitosan biopolymer and the pH of the
release medium, especially within the burst region. Briefly, it is
necessary to remind that cargoes encapsulated in biodegrad-
able polymeric matrices/NPs are released by three mechanisms
taking place in sequence: (i) desorption from the particle
surface, (ii) diffusion and readsorption through the pores of
the polymeric network, and (iii) degradation and erosion of
the polymeric network. Also, solution pH may have affected
the ζ-potential values and sizes (see Figure S4, for example) of
the polymeric NPs.25 For example, CSNPs made of CM had a
ζ-potential of 25.4 ± 1.0 mV at pH 5.0, 5.1 ± 0.8 mV at pH
7.0, and 52.2 ± 1.4 mV at pH 3.0. Conversely, for CSNPs
using C12Mc, the ζ-potentials obtained were 22.7 ± 1.1, 35.2
± 1.1, and 48.3 ± 2.7 mV at pH values of 3.0, 5.0, and 7.0,
respectively. The extent of siRNA release from the different
derivatized and nonderivatized CSNPs generally followed the
sequence pH 7.4 > pH 5.5 > pH 2.0. Therefore, when the
solution pH is larger than the pKa of TPP and siRNA, CSNPs
are highly negatively charged and inner electrostatic repulsions
should facilitate a faster siRNA release. At pH 5.5, such forces
were diminished and cargo molecules would be released by
simple diffusion. At pH 2.0, the chitosan amine groups were
entirely protonated and the cargo release rate was much lower.
In this case, siRNA might have acted as an additional “cross-
linker”, thanks to the electrostatic attractions with the
backbone and NH3
+ groups of chitosan.10,56,57
The observed release profiles denoted a certain dependence
on the chitosan molecular weight (Figure 7a). In particular,
CM-based CSNPs exhibited a more sustained release than CL-
and CH-based ones. This observation could be explained on
the basis that CL-based CSNPs might not have completely
compacted siRNA into stable particles, allowing a faster
release.58,59 Meanwhile, CH-based CSNPs would have a lower
cross-linking density than CM-based ones (larger chitosan/
TPP ratio), thus inducing the formation of a less compact and
more porous polymeric network.60
The hydrophobization of chitosan chains also had a clear
influence on the siRNA release rates, where both the side-chain
length and substitution degree played an important role. Li et
al. analyzed the permeation and diffusion of encapsulated
vitamin B2 within unmodified and alkylated CNPs at different
pH values.61 These authors found that drug release from
unmodified CNPs increased when raising the solution pH as a
consequence of the dissociation and reconstruction of
hydrogen bonding. In basic medium, the dissociation of
hydrogen bonds lowered the intermolecular interaction force
between the side chains and the polymeric network, rendering
it loose and more porous and, thus, the drug diffused out more
easily. Conversely, for alkylated CNPs, drug permeation and
diffusion decreased as the solution pH increased. In acidic
medium, both permeation and diffusion diminished with the
increase in the alkyl side-chain length, whereas the opposite
behavior was found under basic conditions. This observation is
in agreement with the results shown here, where C8-modified
CSNPs displayed, in general, faster release profiles than C12-
modified ones under acidic conditions, whereas the opposite
trend was found at pH 7.4. The elongation of the side chains
increased the hydrophobicity of the polymeric network within
the NPs, which, in turn, hindered the outward diffusion of
siRNA through the NP matrix. Under basic conditions, an
enhancement of diffusion was noted as the number of carbon
atoms in the side chain increased, likely related to a larger
steric hindrance and excluded volume effects. The extent of
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siRNA release was reduced as the substitution degree in the
chitosan backbone increased as a consequence of the larger
density of the particle core, eventually restricting the siRNA
diffusion out of the particles.
3.7. In Vitro Cell Biocompatibility. We next evaluated
the potential cytotoxicity of both CNPs and CSNPs after cell
NP uptake and internalization by measuring cell metabolic
activities via the CCK-8 proliferation assay in two different cell
lines, human cervical cancerous HeLa and mice RAW 264.7
macrophage cells. Different variables such as NP concen-
tration, exposure time, and the nature of the NP (hydro-
phobicity) were analyzed. HeLa cells were chosen since they
represent a classical immortalized tumoral cell line to test in
vitro the efficacy of new drugs/formulations for cancer
treatment. Macrophages are one of the principal immune
effector cells that play essential roles as secretory, phagocytic,
and antigen-presenting cells in the immune system. We chose
RAW 264.7 macrophage cells since they also display a high
sensitivity to potentially toxic chemicals/compounds.62−64
C8Mb- and C12Mc-based CSNPs were selected as examples
of extreme derivatizations (8Mb NPs possess short side chains
and low substitution degree, whereas 12Mc NPs have longer
side chains and much higher substitution degree), and also
showed some of the best physicochemical properties in terms
of particle sizes and surface charges, siRNA protection, serum
stability, and sustained release profiles. In addition, CM-based
CSNPs were selected as controls for comparison.
Figure 8 shows the cell viabilities of the selected CNPs and
CSNPs in both HeLa and RAW 264.7 cell lines after 24 and 48
h of incubation (see also Figure S5 in SI for additional data).
As observed in this figure, HeLa cells were more sensitive than
macrophages to the presence of CNPs and CSNPs, in
agreement with previous observations.65 In HeLa cells, cell
viability was dose dependent for CNPs and, especially, for
CSNPs. Such dependence is not particularly observed in
macrophages, except for the highest particle concentrations
tested.17,66 Nevertheless, the present biopolymeric NPs were
observed to be nontoxic to cells, with viabilities always above
50%, except at the highest concentration (2 mg/mL) after 48 h
of incubation.67 In general, it was also observed that cell
toxicity was relatively larger at longer incubation times.
Moreover, the incorporation of siRNA into the CSNPs
rendered them less toxic to cells than the empty ones
(CNPs), especially in macrophages.
Figure 8. Cell survivals for (a, b) CNPs and (c, d) CSNPs in (a, c) HeLa cells and (b, d) macrophages. Solid symbols represent incubation for 24
h, whereas open symbols for 48 h. (■, □) Medium-molecular-weight chitosan, (●, ○) 8Mb, and (▲, △) 12Mc.
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It was also noted that differences in survival rates were also
cell-type dependent. In nonphagocytic cells such as HeLa,
cationic surface charges and small sizes for most NPs
correlated with higher cellular uptakes (see below) and greater
cell cytotoxicities. Conversely, phagocytes such as macro-
phages and monocytes are more sensitive to the presence of
bigger and negatively charged NPs. The presence of serum
appeared to reduce NP uptake in nonphagocytic cells but
increase NP uptake in phagocytic ones.68,69 For HeLa cells, it
was found that C8Mb and CM CNPs have similar ζ-potentials,
but C8Mb particles exhibited lower survival rates at 48 h of
incubation. For RAW 264.7 cells, the opposite trend was
found. Surprisingly, when siRNA was incorporated inside the
derivatized CSNPs, higher survival rates in both kinds of cell
lines were detected (see Figure S5 in SI). Importantly, CSNPs
with a 12-carbon alkyl chain chitosan derivative achieved
higher biocompatibility compared to the 8-carbon-based ones
and, generally, cell toxicity progressively decreased upon
increasing the level of substitution of the polymeric backbone
when compared to their unmodified homologues (see Figure
S5 in SI). The reason for such behavior is still unclear, but it
might be related to the enhanced hydrophobicity of the
derivatized CSNPs.
To further elucidate the influence of the type and extent of
chitosan hydrophobization on cell viability, relative cell
toxicities (Δ) were calculated. Δ is defined as the difference
in cell survival in the presence of CNPs and CSNPs. Δ > 0
indicated that CSNPs induced lower cellular survival rates than
CNPs, whereas Δ < 0 indicated the opposite behavior.
Chitosan hydrophobization effectively displayed a positive
effect on cell viability, and the type and extent of modification
played a key role. It was observed that CSNPs were more
biocompatible than CNPs, except in HeLa cells after 48 h of
incubation (see Figure S6 in SI).
3.8. Cellular Uptake and Transfection Efficiency. To
analyze the in vitro cellular uptake and transfection efficiency
of CSNPs, fluorescence microscopy and flow cytometry
experiments were carried out. A FITC-labeled scrambled
RNA oligo was used as cargo to effectively confirm the particle
internalization and cargo release inside the cell cytoplasms.
CSNPs produced from C8Mb and C12Mc derivatives of
chitosan were tested as optimal siRNA carriers, whereas the
CM-based ones were used as a reference. Figures 9 and S7
show the temporal evolution of particle internalization inside
HeLa and RAW 264.7 cells, respectively. Cellular uptake was
monitored in macrophages for 2 and 6 h, whereas in HeLa
cells, lapse times of 6, 12, and 24 h were used. The choice of
different time points was based on the strong phagocytic
activity of macrophages, which rapidly engulf a wide variety of
foreign agents such as pathogens, particles, apoptotic cells,
constituting a defense mechanism of the host.70
Figure 9 depicts a progressive particle accumulation and
subsequent siRNA release as shown by the enhancement of the
green fluorescence from the dye-labeled oligo throughout
incubation. Interestingly, CSNPs formulated with derivatized
chitosan resulted in a progressive accumulation of siRNA in
HeLa cells, where the fluorescence pattern turned red to
orange-green in the merged images. However, the CSNPs
bearing unmodified chitosan displayed a less intense
fluorescent signal, which could be ascribed to the lower
amount of siRNA loaded, as compared to those with modified
chitosan. For C8Mb- and C12Mc-CSNPs, the fluorescence was
rather intense after 6 h of incubation, in agreement with their
slightly larger cargo release rates at short incubation times (see
Figure 7). However, the fluorescence signal after 12 h for
C12Mc-CSNPs was surprisingly diminished, whereas at 24 h, it
was recovered. These findings would support our hypothesis
regarding the initial siRNA release from the outermost shell of
the C12Mc-CSNPs shortly after incubation, followed by its
slow diffusion from the NPs’ core (see the discussion below).
To additionally confirm that siRNA was released inside the
cells, three-dimensional (3D) reconstructions of z-stack images
in both kinds of cells were performed. The reconstructed
images (Figure S8 in SI) allowed us to confirm that siRNA was
effectively delivered to and diffused along the cell cytoplasm.
Similarly, NP accumulation inside RAW 264.7 macrophages
increased over time, namely, for CM-CSNPs, which manifested
the highest cell uptake as opposed to the observations in HeLa
cells. The elevated levels of toxicity of CM-CSNPs, previously
observed, may correlate to their higher cell uptake (Figure S7).
Moreover, the observed fluorescence intensity was lower for
C8Mb-CSNPs than for C12Mc-ones. Also, the resulting
fluorescence pattern visualized for C12Mc-CSNPs appeared
mostly punctuated, suggesting particle aggregation.
Finally, a quantitative analysis of the particle uptake and
subsequent transfection in terms of the percentage of FITC
Figure 9. (a) Fluorescence microscopy images of cellular uptake and
intracellular distribution of FITC-siRNA (green channel) in HeLa
cells for 6, 12, and 24 h. The blue fluorescence stemmed from cell
nuclei stained with DAPI and the red fluorescence from the cell
cytoplasm stained with BODIPY Phalloidin. Microphotographs were
presented as merged images to facilitate their understanding. Scale
bars are 10 μm. (b) Transfection efficiency of FTIC-siRNA in HeLa
cells measured by flow cytometry using CM-, C8Mb-, and C12Mc-
CSNPs. Nontransfected HeLa cells were used as a negative control,
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fluorescence inside HeLa cells was also performed by means of
flow cytometry. Figure 9b shows that cells transfected with
CM-CSNPs displayed a low fluorescence during the selected
incubation period. This could be a result of the lower LCs
attained as well as the slower release rates observed for this
class of NPs in solutions of pH 5.5−7.4 (see Table S2 and
Figure 7a). Moreover, cells transfected with C8Mb-CSNPs
displayed a rather similar fluorescence signal, ca. 20%, as those
transfected with CM-CSNPs after 24 h of incubation;
conversely, at 48 h, the extent of transfection largely increased
up to 70%, similar to that of Lipofectamine 2000 used as a
positive control. Finally, C12Mc-CSNPs achieved comparable
levels of transfection with the control at 24 h, which
substantially declined after 48 h of transfection. This behavior
can be a consequence of a stronger interaction of this type of
NPs with cell membranes, facilitating a faster particle cell
uptake as well as a slightly quicker cargo release compared to
those of C8Mb-based and unmodified ones (see Figure 7).
Indeed, it has been already suggested that hydrophobic side
units in polymeric nanocarriers may increase the transfection
efficiency through modulation of NP interactions with cells,
enhancing their adsorption on the cellular surface and
subsequent uptake.58,71,72 Also, hydrophobic segments in
polymeric nanocarriers may help in the disassembly of
chitosan/DNA and chitosan−siRNA NPs to facilitate the
release of the genetic material that would, otherwise, be
strongly bound through ionic interactions to the polymeric
backbone. Hence, such favorable characteristics of the
hydrophobic side chains, grafted onto chitosan, may account
for the prominent transfection efficiencies obtained in this
work when compared to the unmodified biopolymer. In this
regard, Liu et al. prepared alkylated chitosans and observed
that the transfection efficiency in a mouse C2C12 cell line
(C3H muscle myoblast) improved with an increase in the
length of the substituted side chain up to eight carbons, which
is in fair agreement with our data.22 Also, Chae et al.
synthesized deoxycholic-acid-modified chitosans as the main
component of nanocarriers, for pEGFP-N1 plasmid DNA
delivery, achieving a more pronounced transfection efficiency
in HEK 293 cells, which was dependent on the degree of
susbstitution.73 Similarly, Hu et al. grafted stearic acid onto the
chitosan backbone to transfect the pDNA pEGFP-C1 into
A549 cells, obtaining larger transfection efficiencies with much
lower cell mortalities.74
3.9. Efficiency of siRNA Gene Silencing. Finally, to
analyze the silencing activity of released siRNA from the
selected derivatized chitosan-based NPs, we monitored the
fluorescence intensity decrease induced by a specific siRNA
against the expression of GFP transfected in modified HeLa
cells using CM-, C8Mb, and C12Mb-CSNPs by means of
fluorescence microscopy and flow cytometry. Standard HeLa
cells as a negative control and nontransfected GFP-HeLa cells
as a positive one were used. siRNA transfected with
Lipofectamine 2000 was a secondary positive reference for
comparison. According to the qualitative analysis by
fluorescence microscopy, depicted in Figure 10a, the intrinsic
fluorescence of cells was almost maintained following trans-
fection up to 6 h, after which its intensity gradually diminished.
Nonetheless, a significant portion of fluorescence 24 h post-
transfection was detected, which could be assigned to (i) the
sustained release of siRNA molecules inside the cytoplasm
and/or (ii) an insufficient time to achieve remarkable
inhibition of protein expression. The GFP inhibition using
C8Mb and C12Mb-CSNPs seemed to be rather larger than
that of CM-CSNPs probably as a consequence of (i) a lower
LC, (ii) a slower release rate, and (iii) a stronger chitosan−
siRNA interaction, which may prevent siRNA dissociation
from the former NPs.72,75
Quantitative analysis of GFP knockdown efficiency was
further conducted in the same cell line by flow cytometry using
CSNPs with the modified and nonmodified chitosans. Here, it
is necessary to remind that a suitable balance between siRNA
protection and efficient siRNA release must be achieved to
obtain simultaneously high levels of transfection and silencing.
Figure 10b shows that C8Mb-CSNPs exhibited the greatest
gene-silencing activity, ca. 30%, at both 24 and 48 h of
incubation and similar to that of the Lipofectamine 2000
positive control. In contrast, the CM-CSNPs suppressed GFP
expression by 10−15%, which can be rationalized on the basis
on their lower LC values, slow release rates, and serum
instability, as described previously. Surprisingly, rather similar
low knockdown efficiencies (ca. 20%) were also noted for
C12Mc-CSNPs despite their much higher LC and particle
uptake. It could be argued that these CSNPs might have
undergone larger siRNA degradation by nucleases, as
confirmed by gel electrophoresis (Figure 6d), probably due
to the presence of some siRNA in the outermost shell of their
surfaces, as previously hypothesized (see Scheme 1). In this
regard, low silencing activities were also observed for particles
prepared by simple complexation of siRNA onto preformed
Figure 10. (a) Gene silencing observed by fluorescence microscopy in
GFP-HeLa cells exposed to chitosan-based NPs loaded with an
siRNA against GFP. Images were taken at 6, 12, and 24 h of
incubation. Chitosans CM, C8Mb, and C12Mc were used. Merged
images are shown. Scale bars are 10 μm. (b) Mean fluorescence
intensity of GFP expressed in HeLa cells after 24 and 48 h of
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chitosan−TPP NPs as a consequence of the inefficient
protection of the genetic material to enzymatic degrada-
tion.10,76 Therefore, in spite of the greater transfection of the
C12Mc-NPs than that of C8Mb-NPs, after 24 h (see Figure 9),
the potential cleavage of siRNA released from the former ones
might have impaired their gene-silencing performance.
4. CONCLUSIONS
In summary, this work entailed hydrophobic modification of
chitosan, prior to its use in NP production via ionotropic
gelation, for siRNA delivery. The structural modifications
introduced had an impact on siRNA loading capacity and
release patterns, as well as on its transfection efficiency and
gene knockdown activity. This was pursued by the alkylation
procedure, where 8, 10, and 12-carbon side chains were grafted
onto the chitosan backbone, at different substitution degrees
(5, 10, and 50%). The obtained experimental data indicated
that the side-chain length played a key role in determining
particle sizes and surface charges, especially at high substitution
degrees, through controlling the nature and extent of
interactions between siRNA and the modified chitosan
backbone, as shown by ITC data. Likewise, the incorporation
of siRNA into the NPs further induced significant changes in
their surface charges as well as sizes, becoming smaller, due to
the compaction of the NP cores. Moreover, enhanced siRNA
EE and LC values were obtained for NPs formulated with the
hydrophobically modified chitosans compared to those of their
homologues prepared with the unmodified chitosan. Besides,
TEM images enabled to view the diverse morphologies of the
NPs produced, where, for instance, the C8M-CSNPs displayed
a smooth surface, whereas the C12M-CSNPs showed a
hairylike structure. This may justify the alteration in the
siRNA release profiles among CSNPs, with the hydrophobi-
cally modified and unmodified chitosan. Concerning stability
against nucleases, chitosans of higher degrees of substitution
and/or longer side chains (>8 carbons) provided lower
protection to siRNA, supposedly because a part of their side
chains was displaced to the surface, and with some siRNA
excluded outward, making it more prone to enzymatic
degradation. Nevertheless, further analyses are warranted to
ascertain this premise and would be revealed in a forthcoming
publication.
On the other hand, hydrophobically modified and base
CSNPs were, in general, nontoxic to HeLa and RAW 264.7
cells, the former showing a dose-dependent response. Similarly,
cell toxicity and uptake were also found to be cell dependent.
Cell internalization and transfection efficiencies were observed
to be larger for the hydrophobically modified CSNPs, with
slightly better GFP knockdown efficiencies, for example, for
C8Mb-CSNPs compared to those for Lipofectamine 2000
control. This observation probably originated from the
particular architecture of this type of CSNPs, where siRNA
was tightly packed in their cores. However, in the case of
C12Mc-CSNPs, for example, a proportion of siRNA adsorbed
onto the surfaces, probably by the excluded volume effect, thus
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